Skip to Main Content

Paper Details

Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations.
Genome Med
15
2018
17q21, 25 loci, 5FU, 6p21, 6p22-p12, ALK1 receptor, Her2, Her2-negative breast cancer, TMEM100, VEGFA, VEGFA gene, anthracyclines, bevacizumab, breast carcinomas, cyclophosphamide, epirubicin, fluorouracil, patients, subclones, taxane, taxanes, tumor, tumor DNA, tumors, vascular endothelial growth factor A
Author NameAffiliation
David C WedgeBig Data Institute, University of Oxford
Ole Christian Lingj??rdeKG Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo
Ole Christian Lingj??rdeUniversity of Oslo
Hans Kristian Moen VollanInstitute for Cancer Research, Oslo University Hospital Radiumhospitalet
Hans Kristian Moen VollanKG Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo
Hans Kristian Moen VollanOslo University Hospital
Peter Van LooCancer Research UK London Research Institute
Anne-Lise B??rresen-DaleInstitute for Cancer Research, Oslo University Hospital Radiumhospitalet
Anne-Lise B??rresen-DaleKG Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo
Anne-Lise B??rresen-DaleInstitute for Cancer Research, Oslo University Hospital Radiumhospitalet
Anne-Lise B??rresen-DaleKG Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo
Vessela N KristensenInstitute for Cancer Research, Oslo University Hospital Radiumhospitalet
Vessela N KristensenKG Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo
Vessela N KristensenAkershus University Hospital
Vessela N KristensenUniversity of Oslo
  • 1 - 15

Datasets

Release 1.2